Axovant sciences

Editor's note: This article was updated after publishing to remove the "Hedge Fund Buyer's Club" section. Axovant Sciences (NASDAQ: AXON) is a late-stage biotech company focused on development of an Alzheimer’s therapy acquired from GlaxoSmithKline. The company hopes to raise $251 million...